Table 4.
Pooled results of recurrence-free survival, progression-free survival and publication bias of comparing various BCG treatment schedules and doses
|
Measurement |
n* |
Case or case control |
Heterogeneity |
Pooled rate / HR |
Begg’s test ( P ) |
Egger’s test ( P ) |
|
|---|---|---|---|---|---|---|---|
| P | I2 (%) | (95% CI) | |||||
|
Recurrence-free survival |
|
|
|
|
|
|
|
| Superficial bladder cancer |
|
|
|
|
|
|
|
| Maintenance vs. Induction |
9 |
521/536 |
0.150 |
12.0 |
0.516 (0.425-0.627) |
0.602 |
0.353 |
| Low-dose vs. Standard-dose |
7 |
998/1018 |
0.831 |
0.00 |
1.162 (1.051-1.285) |
1.000 |
0.126 |
| BCG plus MMC vs. BCG |
6 |
416/563 |
<0.001 |
79.1 |
0.726 (0.490-1.075) |
0.452 |
0.334 |
| BCG plus MMC vs. MMC |
3 |
213/225 |
0.297 |
17.7 |
0.854 (0.663-1.099) |
0.296 |
0.132 |
| BCG plus Epirubicin vs. BCG |
3 |
124/152 |
0.652 |
0.00 |
0.618 (0.384-0.993) |
1.000 |
0.538 |
| BCG plus IFN-α2b vs. BCG |
2 |
383/342 |
0.621 |
0.00 |
1.075 (0.859-1.345) |
1.000 |
NA |
| High-risk NMIBC |
|
|
|
|
|
|
|
| Maintenance vs. Induction |
5 |
353/362 |
0.272 |
22.4 |
0.515 (0.411-0.646) |
0.086 |
0.032 |
| BCG plus MMC vs. BCG |
3 |
314/298 |
<0.001 |
89.8 |
0.852 (0.449-1.617) |
1.000 |
0.689 |
| BCG plus MMC vs. MMC |
2 |
123/133 |
0.119 |
58.7 |
0.797 (0.477-1.330) |
1.000 |
NA |
| BCG plus Epirubicin vs. BCG |
2 |
100/102 |
0.556 |
0.00 |
0.544 (0.302-0.980) |
1.000 |
NA |
|
Progression-free survival |
|
|
|
|
|
|
|
| Superficial bladder cancer |
|
|
|
|
|
|
|
| Maintenance vs. Induction |
7 |
452/488 |
0.380 |
6.20 |
0.740 (0.572-0.957) |
0.764 |
0.399 |
| Low-dose vs. Standard-dose |
6 |
961/981 |
0.829 |
0.00 |
1.151 (0.853-1.554) |
0.452 |
0.112 |
| BCG plus MMC vs. BCG |
3 |
314/298 |
0.001 |
85.3 |
0.602 (0.181-1.999) |
1.000 |
0.420 |
| BCG plus MMC vs. MMC |
3 |
213/225 |
0.827 |
0.00 |
0.927 (0.482-1.784) |
1.000 |
0.493 |
| BCG plus Epirubicin vs. BCG |
2 |
100/102 |
0.980 |
0.00 |
0.513 (0.132-1.987) |
1.000 |
NA |
| High-risk NMIBC |
|
|
|
|
|
|
|
| Maintenance vs. Induction |
5 |
353/362 |
0.581 |
0.00 |
0.722 (0.548-0.951) |
0.806 |
0.311 |
| BCG plus MMC vs. BCG |
3 |
314/298 |
0.001 |
85.3 |
0.602 (0.181-1.999) |
1.000 |
0.420 |
| BCG plus MMC vs. MMC |
2 |
123/133 |
0.813 |
0.00 |
0.829 (0.387-1.773) |
1.000 |
NA |
| BCG plus Epirubicin vs. BCG | 2 | 100/102 | 0.980 | 0.00 | 0.513 (0.132-1.987) | 1.000 | NA |
NA not applicable. Significant datas are emphasized in bold.
* Number of included studies.